Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May;24(3):e116-e119.
doi: 10.1111/hae.13434. Epub 2018 Mar 24.

Reagent substitutions in the Centers for Disease Control and Prevention Nijmegen-Bethesda assay for factor VIII inhibitors

C H Miller  1 , A B Payne  1 , J Driggers  1 , D Ellingsen  1 , B Boylan  1 , C J Bean  1
Affiliations

Reagent substitutions in the Centers for Disease Control and Prevention Nijmegen-Bethesda assay for factor VIII inhibitors

C H Miller et al. Haemophilia. 2018 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

DISCLOSURES

The authors state that they have no interests which might be perceived as posing a conflict or bias. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

Figures

FIGURE 1
FIGURE 1
Stability over 2-h incubation at 37°C of a 1:1 mixture of normal pool plasma (NPP) and diluent. (A). Change in factor VIII (FVIII) activity and pH of NPP unbuffered or buffered with imidazole or HEPES with factor VIII-deficient plasma (FVIIIDP), 4% bovine serum albumin (BSA) or an inhibitor-negative patient plasma. (B). Imidazole-buffered NPP with FVIIIDP, BSA, imidazole-buffered BSA (IB-BSA) and imidazole buffer (IB). Mean of duplicate determinations on triplicate specimens
See this image and copyright information in PMC

Comment on

References

    1. Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van Den BH, Srivastava A For the Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12:1935–1939. - PubMed
    1. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost. 1995;73:247–251. - PubMed
    1. Peerschke EIB, Castellone DD, Ledford-Kraemer M, Van CE, Meijer P NASCOLA Proficiency Testing Committee. Laboratory assessment of factor VIII inhibitor titer. Am J Clin Pathol. 2009;131:552–558. - PubMed
    1. Verbruggen B, van Heerde W, Novakova I, Lillicrap D, Giles A. A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen modification of the Bethesda factor VIII:C inhibitor assay. Thromb Haemost. 2002;88:362–364. - PubMed
    1. Kershaw GW, Chen LS, Jayakodi D, Dunkley SM. Validation of 4% albumin as a diluent in the Bethesda assay for FVIII inhibitors. Thromb Res. 2013;132:735–741. - PubMed